CN105534848B - A kind of cosmetics or medical composition and its use - Google Patents

A kind of cosmetics or medical composition and its use Download PDF

Info

Publication number
CN105534848B
CN105534848B CN201511016655.9A CN201511016655A CN105534848B CN 105534848 B CN105534848 B CN 105534848B CN 201511016655 A CN201511016655 A CN 201511016655A CN 105534848 B CN105534848 B CN 105534848B
Authority
CN
China
Prior art keywords
hyaluronic acid
group
cell
umbilical cord
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201511016655.9A
Other languages
Chinese (zh)
Other versions
CN105534848A (en
Inventor
任莹莹
金百华
何进琼
王荣
邓云涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SICHUAN NEW LIFE STEM CELLS TECHNOLOGY Co Ltd
Original Assignee
SICHUAN NEW LIFE STEM CELLS TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SICHUAN NEW LIFE STEM CELLS TECHNOLOGY Co Ltd filed Critical SICHUAN NEW LIFE STEM CELLS TECHNOLOGY Co Ltd
Priority to CN201511016655.9A priority Critical patent/CN105534848B/en
Publication of CN105534848A publication Critical patent/CN105534848A/en
Application granted granted Critical
Publication of CN105534848B publication Critical patent/CN105534848B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a kind of cosmetics or pharmaceutical composition, contain following component in the every 10ml of the composition：Mescenchymal stem cell 5 × 106~5 × 107A, 0.01~0.1g of hyaluronic acid, 0.05~0.2ml of human albumin, surplus are water.The present invention also provides the purposes of the composition.The present composition is good to skin injury repairing effect, has a good application prospect.

Description

A kind of cosmetics or medical composition and its use
Technical field
The invention belongs to cosmetic fields and drug field, and in particular to a kind of cosmetics or pharmaceutical composition and its use On the way.
Background technology
Mescenchymal stem cell (MSC) is a kind of adult stem cell with multi-lineage potential, can be from marrow, periphery It being obtained in the Various Tissues such as blood, fat, umbilical cord, mescenchymal stem cell can not only secrete a large amount of bioactie agent, but also Also contain abundant bioactive substance into the cell, it can be with Effective Regulation body signal transduction, activating human body stem cell, Jin Ersheng Rationality reparation or replacement body injury, senile cell etc., mescenchymal stem cell is in cell transplantation, gene therapy, beauty shield at present Skin etc. has been to be concerned by more and more people.
Human umbilical cord mesenchymal stem cells (human umbilical cord mesenchymal stem cells, hUC- MSCs it is) mescenchymal stem cell being present in neonatal umbilical cord, is obtained when individual is born, the mesenchyma phase with other sources Than having abundance, convenient material drawing, when acquisition not to cause new pain and wound to donor；Immunogenicity is relatively low；? The unique advantages such as external proliferation and differentiation capability is strong, have broad application prospects in disease prevention and cure and beauty and skin care field.
Hyaluronic acid (HA), also known as sodium hyaluronate, are a kind of acid mucopolysaccharides, are distributed widely in skin, cartilaginous tissue and pass It saves in the tissues such as synovia, HA has good water retention property, biocompatibility and high osmosis, is referred to as ideal natural guarantor The wet factor, is widely used in cosmetics at present.
Human albumin is a kind of blood product, is extracted from the blood plasma of people that main function is to increase blood volume and maintenance blood Colloid osmotic pressure is starched, clinic is mainly used for the prevention of oedema or ascites, Hypoproteinemia caused by shock, hepatic sclerosis and nephrosis In.
There is presently no mescenchymal stem cell, hyaluronic acid and human albumin combination are prepared cosmetics or pharmaceutical composition Report.
Invention content
The present invention provides a kind of cosmetics or pharmaceutical composition, contain following component in the every 10ml of the composition：Between Mesenchymal stem cells 5 × 106~5 × 107A, 0.01~0.1g of hyaluronic acid, 0.05~0.2ml of human albumin, surplus are water.
Further, following component is contained during the composition is per 10ml：Mescenchymal stem cell 2 × 107A, hyaluronic acid 0.05g, human albumin 0.15ml, surplus are water.
Wherein, the mescenchymal stem cell is human umbilical cord mesenchymal stem cells；The water is water for injection.
Further, the preparation method of the human umbilical cord mesenchymal stem cells is：Umbilical cord is taken, aseptically, is used Tissue block method cultivates to obtain；It is described to take umbilical cord to take 5-10 root umbilical cords to mix.
Wherein, the hyaluronic acid is the hyaluronic acid that molecular weight is 3000D~10KD.
Composition of the present invention, it is added using mescenchymal stem cell, hyaluronic acid, human albumin as active constituent Enter the preparation that on cosmetics or pharmaceutically acceptable auxiliary material or complementary ingredient are prepared.
Further, the preparation is liquid preparation.
Further, the preparation is microneedle injection agent.
The purposes that the present invention also provides above-mentioned compositions in preparing cosmetics.
The present invention also provides purposes of the above-mentioned composition in preparing the drug for repairing skin injury.
It is generally believed that umbilical cord mesenchymal stem cells, hyaluronic acid have certain reparation skin injury effect, and the white egg of people It is white only to maintain plasma colloid osmotic pressure, the dynamic equilibrium of moisture between tissue and blood vessel is adjusted, does not have the work for repairing damage With.
The present composition, can be notable by the specific proportioning of umbilical cord mesenchymal stem cells, hyaluronic acid, human albumin Skin injury is repaired, significant effect is applied in combination better than mescenchymal stem cell with hyaluronic acid, three in the present composition kind Component has played synergistic function.
The composition of the present invention, which has, prevents and repairs skin injury, slows down aging, crease-resistant and Bearberry Extract injects skin Skin skin corium can promote skin cell metabolism, repair and replace aged cells；Promote subcutaneous collagen albumen Fast back-projection algorithm, Make skin-tightening, gloss, bullet profit；Achieve the purpose that quick and long-acting reparation skin.And cell does not occur for the present composition Safety can be used in aggregation.
Obviously, the above according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific implementation mode of form by the following examples remakes further specifically the above of the present invention It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on the above of the present invention The technology realized all belongs to the scope of the present invention.
Description of the drawings
Fig. 1 is P5 for MSC cell surface marker figures.
Fig. 2 is the microscope observation chart (× 4) of formula 1 in test example 1.
Fig. 3 is the microscope observation chart (× 4) of formula 1 in test example 1.
Fig. 4 is the microscope observation chart (× 4) of formula 1 in test example 1.
The surface of a wound figure that the big figures of Fig. 5 are 40 seconds after rabbit skin of back laser irradiation；Small figure is partial enlarged view.
The histopathology HE colored graphs that Fig. 6 is 40 seconds after irradiation, it is seen that Epidermal necrosis, high dermis involvement, part skin Skin appendicle structure is destroyed, blood vessel dilatation hyperemia (× 20).
Fig. 7 left figures are experiment the 6th day, the recovery situation figure of model control group, it is seen that the surface of a wound still has thick scab shell to cover；Right figure For experiment the 6th day, model control group pathology HE colored graphs, it is seen that part promoting epidermization, but still have segmental defect, high dermis lacks It damages, has more inflammatory cell infiltration (× 50) in epidermis and corium.
Fig. 8 left figures are experiment the 6th day, the surface of a wound situation map of present composition microneedle injection group, it is seen that most of scab shell It has been fallen off that, but substrate still compares flush；Right figure is to test the 6th day, present composition microneedle injection group pathology HE colored graphs, It can be seen that there is a little thin scab above epidermis, epidermis is substantially continuous, but structure owes clear, has a small amount of inflammatory cell to soak in epidermis and corium Moisten (× 50).
Fig. 9 left figures are to test the 6th day, model control group TNF-α immunohistochemical staining situation map, and yl moiety represents in figure TNF-α positive expression (× 40)；Right figure is experiment the 6th day, present composition microneedle injection group TNF-α immunohistochemical staining feelings Condition figure, yl moiety represents TNF-α positive expression (× 40) in figure.
Figure 10 left figures are experiment the 12nd day, model control group recovery situation figure, it is seen that most of scab shell has fallen off, substrate Flush, slightly oedema；Right figure is experiment the 12nd day, model control group pathology HE colored graphs, it is seen that part promoting epidermization, but still have Segmental defect, high dermis defect have more inflammatory cell infiltration (× 50) in epidermis and corium.
Figure 11 left figures are experiment the 12nd day, present composition microneedle injection group recovery situation figure, it is seen that the surface of a wound base This healing；Right figure is experiment the 12nd day, present composition microneedle injection group pathology HE colored graphs, it is seen that the surface of a wound restores just substantially Normal skin texture (× 50).
Specific implementation mode
In the following examples, the experimental methods for specific conditions are not specified, according to conventional methods and conditions, or according to kit Specification selects.
Experiment reagent is as follows：
Reagent Buy producer
CD45-FITC CD90-FITC Coulter companies of the U.S.
HLA-DR-FITC Coulter companies of the U.S.
CD105-PE Coulter companies of the U.S.
DMEM/F12 culture mediums GIBICO companies of the U.S.
Trypsase Sigma Co., USA
Fetal calf serum Australian PAA
Serum free medium GIBICO companies of the U.S.
The hyaluronic acid of low molecular weight (3000-10KD) Shandong Fu Ruida Pharmaceutical Groups company
Albumin Rongsheng Pharmaceutical Co., Ltd., Chengdu
The preparation of 1 present composition of embodiment
One, human umbilical cord mesenchymal stem cells are obtained
1, umbilical cord source
Fetus parent signs umbilical cord and donates insider's letter of consent, the antibody of HCV of antenatal exaination puerpera, AIDS I/II antibody of virus, hepatitis B virus antigen and syphilis helicoid antibody.Inspection result qualification is acquired while childbirth Umbilical cord, bleeding of the umbilicus.Bleeding of the umbilicus ensures the adopted virus-free pollution of umbilical cord for detecting virus.
2, preparation method：
(1) umbilical cord of 10 viral diagnosis qualifications of donations is shredded into 1mm with eye scissors under sterile conditions3Size It is uniformly mixed after the tissue block of left and right.
(2) uniformly mixed tissue block is evenly laid out in the plastic culture dish of a diameter of 100mm, culture completely is added Base [90% (v/v) DMEM/F12+10% (v/v) fetal calf serum], cultivates tissue block, liquid was changed every three days, when P0 generations When MSC degree of converging is up to 75~85%, the supernatant containing serum is discarded, harvests cell.
(3) by the cell of harvest with 3000/cm2Density is inoculated into T75 culture bottles, and uses serum free culture system Culture.When cell growth to degree of converging 75~85%, cell is harvested, 10% DMSO is added, cell concentration is adjusted to 1.0~ 10.0×106A/ml/ pipes, are stored in liquid nitrogen container after using Programmed freezing instrument to freeze as seed bank cell (i.e. P1 is for cell). Motility rate measurement, motility rate 96.9%, Sterility testing are carried out for cell to obtained P1：As a result it is sterile.
(4) recovery seed bank cell is measured on demand, is enlarged culture, and recovery Cell viability is 94.5%.By seed bank Cell is with 3000/cm2Density is inoculated into T75 culture bottles, and uses serum free culture system culture.When cell growth to remittance Right 75~85%, cell (i.e. P2 is for cell) is passed on, then with 8000/cm2Density is inoculated into T225 culture bottles. When cell growth to degree of converging 75~85%, cell (i.e. P3 is for cell) is passed on, is repeated operation until harvesting P5 For cell, by 1.0~10.0 × 107A cell/ml density freezes, as use umbilical cord mesenchymal stem cells.
3, result
P5 is taken to carry out flow cytometer detection for cell suspension, testing result is shown in Table shown in 1, Fig. 1.
Immunophenotypes of 1 P5 of table for MSC cells
By table 1, seen in Fig. 1, cell height expresses CD90, CD105, but does not express CD45, HLA-DR, meets and fills between people's umbilical cord The surface marker feature of matter stem cell.
The human umbilical cord mesenchymal stem cells of the present invention are obtained using mixing umbilical cord culture, obtained mescenchymal stem cell matter Amount is stablized, and industrialized production quality control is conducive to.
Two, the preparation of the present composition
After 37 DEG C of recoveries of umbilical cord mesenchymal stem cells of above-mentioned Cord blood, low molecular weight (3000-10KD) is added Hyaluronic acid, human albumin and sterile ultra-pure water, it includes umbilical cord mesenchymal stem cells a concentration of 2 × 10 to make every 100ml aqueous solutions8 A, hyaluronic acid 0.5g, human albumin 1.5ml, surplus are water for injection.
Beneficial effects of the present invention are illustrated below by way of test example.
The screening test of 1 present composition of test example
Formula 1：10ml aqueous solutions include umbilical cord mesenchymal stem cells a concentration of 2 × 107A, hyaluronic acid 0.05g, surplus For water for injection.
Formula 2：10ml aqueous solutions include umbilical cord mesenchymal stem cells a concentration of 2 × 107A, hyaluronic acid 0.05g, people are white Albumen 0.1ml, surplus are water for injection.
Formula 3：10ml aqueous solutions include umbilical cord mesenchymal stem cells a concentration of 2 × 107A, hyaluronic acid 0.05g, people are white Albumen 0.15ml, surplus are water for injection.
It is observed under the microscope after each formula is stored 1h, 4h, 8h, observation result is shown in Fig. 2-4, is shown in Table after result is counted 2。
The concentration class result of 2 different formulations of table
Formula 1h concentration class 4h concentration class 8h concentration class
Formula 1 ++ +++ +++
Formula 2 + + +
Formula 3 - - -
Germicidal efficacy aggregation extent with+indicate, do not assemble with-indicate.Little aggregates with "+" moderate assemble with "+ + ", Severe aggregation uses " +++ ".
By Fig. 2-4, table 2 as it can be seen that moderate is assembled after 1 storage 1h of formula, severe aggregation is already belonged to after 8h, if It is injected into skin corium, capillary is entered, easily forms embolism；Find there are little aggregates after 2 storage of formula；Formula 3 passes through 8h After storage, cell is still evenly distributed in injection, is not assembled.
Therefore, formula 3 is safe to use, and skin repair can be used in a manner of microneedle injection etc., compared with formula 1,2, has Significant advantage.
The application of 2 present composition of test example
One, method
Method：Choose 2 kilograms or so Japan large ear rabbits 30 of weight, half male and half female.After depilation, local anaesthesia, wavelength is used 1064nm laser, spot diameter 3mm, energy density 12J/cm2, smooth bark distance 7cm, 30 seconds time irradiation family rabbit back, cause As deep as the damage of corium.
Then rabbit is divided into 5 groups, every group 6.
1st group is model control group：Only it is not administered according to laser；
2nd group is mescenchymal stem cell+hyaluronic acid positive controls：Microneedle injection mescenchymal stem cell+hyaluronic acid (10ml aqueous solutions include umbilical cord mesenchymal stem cells a concentration of 2 × 107A, hyaluronic acid 0.05g) 20uL/cm2, it is equivalent to 4 × 104A cell/cm2, it is administered once a day；
3rd group is fibroblast growth factor (FGF) positive controls：By fibroblastic growth
The factor is uniformly sprayed on the surface of a wound, every time 2 spray (85IU/cm2/ d), it is administered once a day；
4th group is microneedle injection liquid group：Microneedle injection liquid prepared by 1 method of microneedle injection embodiment
20uL/cm2, it is equivalent to 4 × 104A cell/cm2, it is administered once daily；
5th group is blank control group：It is not administered according to laser.
At the 3rd, 6,9,12 day, surface of a wound decrustation time and healing time are visually observed, skin histology is taken to do pathology HE dyeing, And in above each time point detection interleukin 6 (IL-6), tumor necrosis factor (TNF-α), succinate dehydrogenase (SDH) and hydroxyl dried meat Propylhomoserin (HYP).
Two, result
It is shown in Table 3-8 and Fig. 5-11.
The 3 each group decrustation time of table compares in (day)
Group number Group Number of animals x±sd
1 Model comparison 6 8.55±1.68
2 Mescenchymal stem cell+hyaluronic acid 6 6.08±0.95*
3 Fibroblast growth factor 6 5.54±0.75*
4 The present composition 6 5.63±0.64*
Compared with model control group, * P<0.01.
By table 3 as it can be seen that compared with model control group, the decrustation time of processing group 2-4 groups significantly reduces (p<0.01), Middle tested group using the present composition right with mescenchymal stem cell+hyaluronic acid group, the fibroblast growth factor positive According to the no significant difference (P of group>0.05), decrustation effect is suitable.
Therefore, the decrustation reparation of damaged skin can be remarkably promoted using the present composition.
4 each group healing time of table compares in (day)
Group number Group Number of animals x±sd
1 Model comparison 6 13.05±0.76
2 Mescenchymal stem cell+hyaluronic acid 6 10.80±1.18*
3 Fibroblast growth factor 6 8.78±0.80*##
4 The present composition 6 8.89±1.22*##
Compared with model control group, * P<0.01；Compared with mescenchymal stem cell+hyaluronic acid, #P<0.05；##P< 0.01。
By table 4 as it can be seen that compared with model control group, the healing time of processing group 2-4 groups significantly reduces (p<0.01)；Its The middle tested group of significant effect using the present composition is better than mescenchymal stem cell+hyaluronic acid group (p<0.01), at fibre Tie up cell growth factor subgroup quite (P>0.05).
Therefore, the healing of damaged skin can be remarkably promoted using cell factor freeze-dried powder of the present invention, effect is filled between being better than Matter stem cell is applied in combination with hyaluronic acid, has unexpected technique effect.
5 each group Interleukin-6 concentration of table compares (ng/ml)
Group number Group Number of animals x±sd
1 Model comparison 6 2428±293
2 Mescenchymal stem cell+hyaluronic acid 6 1523±680*
3 Fibroblast growth factor 6 1277±405*#
4 The present composition 6 952±203*##
5 Blank control 6 813±597*##
Compared with model control group, * P<0.01；Compared with mescenchymal stem cell+hyaluronic acid group, #P<0.05；##P< 0.01。
6 each group TNF-α integral optical density of table compares (× 108)
Group number Group Number of animals x±sd
1 Model comparison 6 0.58±0.11
2 Mescenchymal stem cell+hyaluronic acid 6 1.39±0.30**
3 Fibroblast growth factor 6 2.46±0.41**#
4 The present composition 6 2.41±0.37**#
5 Blank control 6 0.15±0.01#
Compared with model control group, * P<0.05, * * P<0.01；Compared with mescenchymal stem cell+hyaluronic acid group, #P< 0.01。
7 each group SDH specific activities of table compare (U/mg albumen)
Group number Group Number of animals x±sd
1 Model comparison 6 0.15±0.05
2 Mescenchymal stem cell+hyaluronic acid 6 0.30±0.10*
3 Fibroblast growth factor 6 0.41±0.05*#
4 The present composition 6 0.39±0.14*#
5 Blank control 6 0.41±0.14*
Compared with model control group, * P<0.01；Compared with mescenchymal stem cell+hyaluronic acid group, #P<0.05.
8 each group HYP concentration of table compares (μ g/mg)
Group number Group Number of animals x±sd
1 Model comparison 6 3.73±0.95
2 Mescenchymal stem cell+hyaluronic acid 6 4.87±0.51*
3 Fibroblast growth factor 6 6.55±1.41#**
4 The present composition 6 6.49±1.41#**
5 Blank control 6 6.61±0.36#**
Compared with model control group, * P<0.05, * * P<0.01；Compared with mescenchymal stem cell+hyaluronic acid group, #P< 0.01。
By table 5-8 as it can be seen that
Compared with model control group, the IL-6 contents of processing group 2-4 groups significantly reduce (p<0.01), wherein using this hair Tested group of IL-6 contents of bright composition are substantially less than positive control mescenchymal stem cell+hyaluronic acid group and fibroblast Growth factor；
TNF-α, the SDH contents of processing group 2-4 groups are significantly increased (p<0.01), wherein using the present composition by TNF-α, the SDH contents of examination group are significantly better than mescenchymal stem cell+hyaluronic acid group, with fibroblast growth factor group phase When.
The HYP contents of processing group 2-4 groups are significantly increased (p<0.05), wherein using tested group of the present composition HYP contents are significantly better than mescenchymal stem cell+hyaluronic acid group, suitable with the HYP contents of fibroblast growth factor group.
Therefore, the present composition can reduce the secretion of IL-6, promote the synthesis and release of TNF-α, mitigate part wound Face inflammatory reaction；Surface of a wound cell SDH activity is improved, accelerates HYP synthesis, to wound healing, with fibroblastic growth The repair of the factor is suitable.
It is generally believed that umbilical cord mesenchymal stem cells, hyaluronic acid have certain reparation skin injury effect, and the white egg of people It is white only to maintain plasma colloid osmotic pressure, the dynamic equilibrium of moisture between tissue and blood vessel is adjusted, does not have the work for repairing damage With.
The present composition, can be notable by the specific proportioning of umbilical cord mesenchymal stem cells, hyaluronic acid, human albumin Skin injury is repaired, significant effect is applied in combination with hyaluronic acid better than mescenchymal stem cell, illustrates in the present composition Three kinds of components have played synergistic function.
To sum up, the present composition is good to skin injury repairing effect, and cell aggregation does not occur for the present composition, Safety can be used；In addition the present composition prepares convenient, suitable large-scale production, therefore has good market prospects.

Claims (8)

1. a kind of cosmetics or pharmaceutical composition, it is characterised in that：Contain following component in the every 10ml of the composition：
Mescenchymal stem cell 2 × 107A, hyaluronic acid 0.05g, human albumin 0.15ml, surplus are water；
The mescenchymal stem cell is human umbilical cord mesenchymal stem cells.
2. composition according to claim 1, it is characterised in that：
The water is water for injection.
3. composition according to claim 2, it is characterised in that：
The preparation method of the human umbilical cord mesenchymal stem cells is：Take umbilical cord, aseptically, cultivated using tissue block method It arrives；It is described to take umbilical cord to take 5-10 root umbilical cords to mix.
4. composition according to claim 1, it is characterised in that：
The hyaluronic acid is the hyaluronic acid that molecular weight is 3000D~10KD.
5. composition according to claim 1, it is characterised in that：
It is added on cosmetics or pharmaceutically acceptable using mescenchymal stem cell, hyaluronic acid, human albumin as active constituent Auxiliary material or the preparation that is prepared of complementary ingredient.
6. composition according to claim 1, it is characterised in that：The preparation is liquid preparation.
7. preparation according to claim 1, it is characterised in that：The preparation is microneedle injection agent.
8. purposes of the composition in preparing the drug for repairing skin injury described in claim 1~7 any one.
CN201511016655.9A 2015-12-29 2015-12-29 A kind of cosmetics or medical composition and its use Active CN105534848B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511016655.9A CN105534848B (en) 2015-12-29 2015-12-29 A kind of cosmetics or medical composition and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511016655.9A CN105534848B (en) 2015-12-29 2015-12-29 A kind of cosmetics or medical composition and its use

Publications (2)

Publication Number Publication Date
CN105534848A CN105534848A (en) 2016-05-04
CN105534848B true CN105534848B (en) 2018-11-02

Family

ID=55814782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511016655.9A Active CN105534848B (en) 2015-12-29 2015-12-29 A kind of cosmetics or medical composition and its use

Country Status (1)

Country Link
CN (1) CN105534848B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106563161A (en) * 2016-11-08 2017-04-19 华南生物医药研究院 Novel drug combination for cosmetic purposes
CN106491646A (en) * 2016-11-08 2017-03-15 华南生物医药研究院 New pharmaceutical composition of collagen secretion and application thereof can be stimulated
CN106562992A (en) * 2016-11-08 2017-04-19 中国人民解放军军事医学科学院野战输血研究所 New method for improving cell viability and promoting vascularization
CN106491647A (en) * 2016-11-08 2017-03-15 华南生物医药研究院 Application of the specific cell pharmaceutical intermixture in beauty and skin care
CN106619721A (en) * 2016-11-08 2017-05-10 中国人民解放军军事医学科学院野战输血研究所 Novel method for enhancing cell viability
CN106581760A (en) * 2016-11-08 2017-04-26 华南生物医药研究院 Special treatment method for enhancing cell activity
CN106729641A (en) * 2016-12-26 2017-05-31 广州赛莱拉干细胞科技股份有限公司 Composition and its application
CN106692951A (en) * 2016-12-26 2017-05-24 广州赛莱拉干细胞科技股份有限公司 Composition and application thereof
CN107519126B (en) * 2017-07-13 2021-05-28 沃昕生物科技(深圳)有限公司 Umbilical cord stem cell wrinkle removing agent and preparation method thereof
CN107550846A (en) * 2017-09-01 2018-01-09 广东唯泰生物科技有限公司 A kind of Stem Cell Activity compound formulation for beauty and skin care and preparation method thereof
CN109730961A (en) * 2019-03-15 2019-05-10 北京康爱瑞浩生物科技股份有限公司 A kind of cosmetics of the culture supernatant containing human umbilical cord mesenchymal stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1431894A (en) * 2000-05-31 2003-07-23 弗雷森纽斯卡比德国有限责任公司 Cosmetic compsn. comprising human serum albumin obtained from transgenic non-human animals
CN102625689A (en) * 2009-05-04 2012-08-01 尼奥斯泰姆公司 Method and composition for restoration of age-related tissue loss in the face or selected areas of the body
CN104490727A (en) * 2014-11-28 2015-04-08 广州赛莱拉干细胞科技股份有限公司 Composition of stem cells and hyaluronic acid and application of composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1431894A (en) * 2000-05-31 2003-07-23 弗雷森纽斯卡比德国有限责任公司 Cosmetic compsn. comprising human serum albumin obtained from transgenic non-human animals
CN102625689A (en) * 2009-05-04 2012-08-01 尼奥斯泰姆公司 Method and composition for restoration of age-related tissue loss in the face or selected areas of the body
CN104490727A (en) * 2014-11-28 2015-04-08 广州赛莱拉干细胞科技股份有限公司 Composition of stem cells and hyaluronic acid and application of composition

Also Published As

Publication number Publication date
CN105534848A (en) 2016-05-04

Similar Documents

Publication Publication Date Title
CN105534848B (en) A kind of cosmetics or medical composition and its use
CN105543313B (en) Human mesenchymal stem cell factor and preparation method and application thereof
CN106109496B (en) Human umbilical cord mesenchymal stem cells extract freeze-drying powder and preparation method
US20190175787A1 (en) Reparative Cell Isolation and Delivery
Karoubi et al. Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells
CN106982821A (en) Umbilical cord mesenchymal stem cells clinic freezes protection liquid composition and application thereof
CN100400655C (en) Engineered extracellular matrix preparation method
CN105056303A (en) Composition, preparation and application thereof
US20080199440A1 (en) Tissue Repair Using Allogenic Dermal Fibroblasts
CN110339147A (en) A kind of composition for external application and application thereof
Deng et al. PF-127 hydrogel plus sodium ascorbyl phosphate improves Wharton’s jelly mesenchymal stem cell-mediated skin wound healing in mice
WO2020130800A1 (en) Stem cell conditioned media
CN105820998A (en) Isolation extraction and culture method for human adipose-derived stem cells (ADSCs) for clinical back-transfusion grade cell therapy
CN100508948C (en) Production for skin beautification and care, and preparation method thereof
CN106659741A (en) Hair growth-promoting function of small-sized stem cells and use thereof
CN103393585A (en) Fibroblast liquid for beauty treatment and preparation method thereof
Willenberg et al. Gelatinized copper–capillary alginate gel functions as an injectable tissue scaffolding system for stem cell transplants
CN102146359A (en) Method for extracting original mesenchymal stem cells from placenta and serum-free amplification
WO2013025763A2 (en) Tissue engineering using injectable, oxidized alginate hydrogels
CN113101303B (en) Preparation method and application of spontaneous apoptotic mesenchymal stem cells
CN110559254A (en) Exosome composition, preparation method and application thereof
CN102781455B (en) Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use
CN109864964B (en) Anti-aging composition containing stem cells and application thereof
CN113171332A (en) Exosome freeze-dried powder, preparation method thereof and skin care product
CN102161981A (en) Method for jointly inducing bone marrow mesenchymal stem cells into sweat gland cells by recombinant protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant